Keywords: busy, period, aventis, firm, drops, ad, compound
Busy period for Aventis as firm drops AD compound, files for first ketolide
Article | 08 March 2000
Aventis Pharma is terminating its development program forpropentofylline in the treatment of Alzheimer's disease, saying that "the decision is a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
